Plasma itraconazole concentrations in patients with neutropenia: Advantages of a divided daily dosage regimen

Therapeutic Drug Monitoring

Volumn 19, Issue 5, 1997, Pages 525-529

  Poirier, Jean Marie ^a   Hardy, Sebastien ^a   Isnard, Françoise ^a   Tilleul, Patrick ^a   Weissenburger, Jacques ^a   Cheymol, Georges ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Dosage regimen; Itraconazole drug monitoring; Patients with neutropenia

Indexed keywords

ANTACID AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HYDROXYITRACONAZOLE; ITRACONAZOLE; OMEPRAZOLE; RANITIDINE; SUCRALFATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; DRUG MONITORING; FOLLOW UP; FRANCE; GASTROINTESTINAL TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKEMIA; LYMPHOMA; MYELODYSPLASIA; MYELOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; DRUG MONITORING; HUMANS; ITRACONAZOLE; LEUKEMIA; LYMPHOMA; MIDDLE AGED; MYCOSES; NEUTROPENIA;

EID: 0031405629     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199710000-00007     Document Type: Article

References (16)

1. Bodet GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989;8:413-37.
2. Van Custen J, Van Gerven F, Janssen PAJ. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987;9:15-32.
3. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23:607-14.
4. Van't Wout JW, Novakova I, Verhagen CAH, et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991;22:45-52.
5. Van Peer A, Woestenborghs R, Heykants J, et al. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol 1989;36:423-6.
6. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989;32: 67-87.
7. Van Custen. The in vitro antifungal spectrum of itraconazole. Mycoses 1989;32:7-13.
8. Boogaerts MA, Verhoef GE, Zachee P, et al. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32:103-8.
9. Poirier JM, Berlioz F, Isnard F, et al. Marked intra- and interpatient variability of itraconazole steady state plasma concentrations. Thérapie 1996;51:163-7.
10. Persat F, Marzullo C, Guyotat D, et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992;28:838-41.
11. Poirier JM, Cheymol G. A rapid and specific liquid chromatographic assay for the determination of itraconazole and hydroxyitraconazole in plasma. Ther Drug Monit 1997;19:247-8.
12. Bradford CR, Prentice AG, Warnock DW, et al. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeoblastic leukaemia. J Antimicrob Chem 1991;28:555-60.
13. Loeuille GA, Berthou C, Hilmarsdottir I, et al. Aspergilloses traitées par l'itraconazole: analyse de 64 cas-revue de la littérature. J Mycol Med 1993;3:1-13.
14. 2-receptors antagonists on the pharmacokinetics of itraconazole, a new oral antifungal. Br J Clin Pharmacol 1989;27:105-6.
15. Hardin TC, Graybill JR, Fetchick R, et al. Pharmacokinetics of itraconazole following oral absorption to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-13.
16. Shaw MT, Spector MH, Ladman AJ. Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. Cancer Treat Rev 1979;6:141-51.